News Releases

The information in press releases posted on the Heat Biologics website were factually accurate on the date of publication. These press releases remain on our site for historical purposes only. Heat Biologics assumes no duty to update the information to reflect subsequent developments or updates. Readers should not rely upon the information in these pages as most-current or accurate after their publication dates.

 

News Releases

Heat Biologics Prices 5,813,950 Shares for Common Stock Offering

DURHAM, NC / ACCESSWIRE / November 17, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced the pricing of an underwritten public offering of...

Heat Biologics Announces Proposed Public Offering of Common Stock

DURHAM, NC / ACCESSWIRE / November 16, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced that it intends to offer for sale shares of its...

Heat Biologics Reports Third-quarter 2017 Results and Corporate Update

DURHAM, NC / ACCESSWIRE / November 13, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, reported financial and clinical updates for the third quarter ended...

Heat Biologics Announces Expected Calendar for Rights Offering

DURHAM, NC / ACCESSWIRE / September 28, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, has filed a registration statement on Form S-1 with the U.S....

Heat Biologics Inc. Reports Second Quarter 2017 Results

DURHAM, NC / ACCESSWIRE / August 14, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company focused on developing immuno-oncology therapies to activate a patient's immune response against cancer, reported financial and clinical updates for...